We are live on
!
Find out more
Rubric Capital Management (New York) Portfolio holdings
AUM
$10.9B
Turnover
31.68%
1-Year Est. Return
70.31%
This Fund
S&P 500
This Quarter
Est. Return
+19.17%
1 Year Est. Return
+70.31%
3 Year Est. Return
+250.68%
5 Year Est. Return
+304.91%
10 Year Est. Return
–
AUM
$10.9B
AUM Growth
+$1.46B
(+15%)
Cap. Flow
+$1.48B
Cap. Flow
% of AUM
13.59%
Top 10 Holdings %
Top 10 Hldgs %
46.43%
Holding
101
New
18
Increased
33
Reduced
12
Closed
14
Avg Time Held Equity + Options
1.6
years
Top 10 Avg Time Held Equity + Options
1.4
years
Top 20 Avg Time Held Equity + Options
1.3
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
1.4
years
Top 20 Avg Time Held Equity only
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fluor
FLR
|
+$246M |
| 2 |
Amazon
AMZN
|
+$226M |
| 3 |
Gildan
GIL
|
+$178M |
| 4 |
Zoom
ZM
|
+$167M |
| 5 |
PennyMac Financial
PFSI
|
+$143M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Constellation Energy
CEG
|
+$200M |
| 2 |
Akamai
AKAM
|
+$149M |
| 3 |
Telephone and Data Systems
TDS
|
+$77.9M |
| 4 |
Adeia
ADEA
|
+$63.7M |
| 5 |
Mercury Insurance
MCY
|
+$60.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.1% |
| 2 | Utilities | 18.51% |
| 3 | Industrials | 14.51% |
| 4 | Consumer Discretionary | 7.69% |
| 5 | Energy | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Talen Energy Corp
TLN
$17B
| $1.38B | 12.7% |
3,602,171
| – | – |
2024 Q3
7 quarters
|
|
2
FTAI Aviation
FTAI
$16.8B
| $812M | 7.45% |
3,000,000
+423,814
| +16% | +$107M |
2025 Q1
5 quarters
|
|
3
Viatris
VTRS
$20B
| $543M | 4.98% |
34,168,743
+668,743
| +2% | +$10.4M |
2025 Q2
4 quarters
|
|
4
Teva Pharmaceutical Industries Limited
TEVA
$47.5B
| $528M | 4.84% |
15,575,000
+325,000
| +2% | +$10.8M |
2023 Q1
13 quarters
|
|
5
Golar LNG
GLNG
$4.7B
| $457M | 4.2% |
9,178,978
| – | – |
2021 Q2
20 quarters
|
|
6
Vistra
VST
$50.9B
| $285M | 2.61% |
1,794,953
+294,953
| +20% | +$45.8M |
2025 Q4
2 quarters
|
|
7
TransAlta
TAC
$4B
| $280M | 2.57% |
20,232,011
+2,450,686
| +14% | +$32.4M |
2021 Q1
21 quarters
|
|
|
8
Fluor
FLR
$6.37B
| $263M | 2.41% |
+5,017,248
| New | +$246M |
2026 Q2
0 quarters
|
|
9
Kiniksa Pharmaceuticals
KNSA
$6.15B
| $256M | 2.35% |
3,999,800
+249,800
| +7% | +$13M |
2022 Q2
16 quarters
|
|
10
BGC Group
BGC
$5.37B
| $254M | 2.33% |
23,800,000
+500,000
| +2% | +$5.59M |
2018 Q3
31 quarters
|
|
|
11
Zoom
ZM
$27.6B
| $239M | 2.19% |
2,766,009
+1,765,003
| +176% | +$167M |
2026 Q1
1 quarter
|
|
|
12
Gildan
GIL
$7.62B
| $232M | 2.13% |
4,500,000
+3,104,210
| +222% | +$178M |
2025 Q3
3 quarters
|
|
13
Arcutis Biotherapeutics
ARQT
$3.32B
| $217M | 1.99% |
8,271,577
| – | – |
2022 Q2
16 quarters
|
|
|
14
Amazon
AMZN
$2.74T
| $215M | 1.97% |
+900,000
| New | +$226M |
2026 Q2
0 quarters
|
|
15
Roivant Sciences
ROIV
$24.3B
| $212M | 1.95% |
6,000,000
+1,000,000
| +20% | +$29.6M |
2022 Q4
14 quarters
|
|
16
Zymeworks
ZYME
$1.78B
| $183M | 1.68% |
7,000,000
| – | – |
2022 Q4
14 quarters
|
|
17
Amcor
AMCR
$19.5B
| $180M | 1.66% |
4,162,030
+2,892,634
| +228% | +$115M |
2026 Q1
1 quarter
|
|
18
Cimpress
CMPR
$1.79B
| $178M | 1.63% |
1,750,000
+120,581
| +7% | +$10.7M |
2025 Q2
4 quarters
|
|
19
Amneal Pharmaceuticals
AMRX
$6.58B
| $176M | 1.61% |
10,168,660
-868,929
| -8% | -$11.9M |
2023 Q2
12 quarters
|
|
20
Nurix Therapeutics
NRIX
$2.59B
| $175M | 1.61% |
7,227,778
+4,753,893
| +192% | +$81M |
2025 Q4
2 quarters
|
|
|
21
Mercury Insurance
MCY
$5.67B
| $164M | 1.51% |
1,541,440
-613,064
| -28% | -$60.4M |
2025 Q1
5 quarters
|
|
|
22
PennyMac Financial
PFSI
$3B
| $148M | 1.36% |
1,700,000
+1,645,273
| +3,006% | +$143M |
2026 Q1
1 quarter
|
|
23
Integra LifeSciences
IART
$1.02B
| $139M | 1.28% |
7,753,934
| – | – |
2024 Q3
7 quarters
|
|
24
Delek US
DK
$4.84B
| $137M | 1.25% |
2,687,449
| – | – |
2024 Q3
7 quarters
|
|
25
Liberty Global Class A
LBTYA
$2.79B
| $134M | 1.23% |
11,752,855
| – | – |
2023 Q4
10 quarters
|
|
Similar funds
Rubric Capital Management (New York)'s Q2 2026 Portfolio in Review
As of Q2 2026, Rubric Capital Management (New York) held 101 positions worth $10.9B, up 15% from $9.44B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Rubric Capital Management (New York) deployed $1.48B of net new capital in Q2 2026, opening 18 new positions and adding to 33 existing holdings. Its largest new stake was Fluor: 5,017,248 shares worth $263M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 28% a quarter earlier, followed by Utilities and Industrials.
On the sell side, the largest reduction was Adeia, an estimated $63.7M trimmed.
- Rubric Capital Management (New York)'s largest Q2 2026 buy was Fluor: 5,017,248 shares worth $263M.
- Rubric Capital Management (New York) added most to Gildan in Q2 2026, an estimated $178M increase.
- Rubric Capital Management (New York)'s biggest Q2 2026 reduction was Adeia, cutting an estimated $63.7M.
- Rubric Capital Management (New York) fully exited Constellation Energy in Q2 2026, selling an estimated $200M.
- Rubric Capital Management (New York)'s ten largest holdings make up 46% of its $10.9B portfolio in Q2 2026.
- Rubric Capital Management (New York) opened 18 new positions and closed 14 in Q2 2026.
- Rubric Capital Management (New York)'s portfolio value rose 15% quarter-over-quarter to $10.9B.
Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.